Petros Pharmaceuticals, Inc. SEC filings PTPI
Petros Pharmaceuticals, Inc. has 257 filings in SEC EDGAR's recent list, going back to Jul 24, 2020. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (bankruptcy, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bankruptcy, Officer or director change
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2026 | Jun 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Jan 1, 2026 |
| 8-K |
Current report
Listing notice
|
Nov 7, 2025 | Nov 3, 2025 |
| 8-K |
Current report
Auditor change
|
Sep 5, 2025 | Aug 29, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 20, 2025 | Jun 16, 2025 |
| 8-K |
Current report
Listing notice
|
May 21, 2025 | May 20, 2025 |
| 8-K |
Current report
Listing notice, Change to shareholder rights, Bylaw or fiscal year change
|
May 2, 2025 | Apr 28, 2025 |
| 8-K |
Current report
Listing notice, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Apr 11, 2025 | Apr 8, 2025 |
| 8-K |
Current report
Auditor change
|
Apr 9, 2025 | Apr 5, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 21, 2025 | Feb 17, 2025 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Jan 24, 2025 | Jan 23, 2025 |
| 8-K | Current report | Dec 16, 2024 | Dec 10, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Nov 21, 2024 | Nov 20, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 18, 2024 | Oct 16, 2024 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Oct 17, 2024 | Oct 11, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 4, 2024 | Oct 1, 2024 |
| 8-K | Current report | Sep 19, 2024 | Sep 16, 2024 |
| 8-K |
Current report
Material agreement
|
Mar 22, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Auditor change
|
Jan 12, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Dec 29, 2023 | Dec 29, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 28, 2023 | Dec 21, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 2, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Sep 15, 2023 | Sep 14, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 15, 2023 | Aug 15, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Jul 13, 2023 | Jul 13, 2023 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Nov 30, 2022 | Nov 29, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 15, 2022 | Nov 15, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 15, 2022 | Aug 15, 2022 |
| 8-K |
Current report
Other events
|
Jul 28, 2022 | Jul 28, 2022 |
| 8-K |
Current report
Listing notice
|
Jun 24, 2022 | Jun 22, 2022 |
| 8-K |
Current report
Other events
|
Apr 26, 2022 | Apr 26, 2022 |
| 8-K |
Current report
Results of operations
|
Apr 4, 2022 | Apr 1, 2022 |
| 8-K/A |
Amended current report
Shareholder vote results
|
Apr 1, 2022 | Dec 22, 2021 |
| 8-K |
Current report
Officer or director change
|
Mar 4, 2022 | Feb 28, 2022 |
| 8-K |
Current report
Material agreement
|
Jan 24, 2022 | Jan 20, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Jan 21, 2022 | Jan 18, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 27, 2021 | Dec 22, 2021 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Dec 23, 2021 | Dec 22, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 1, 2021 | Nov 29, 2021 |
| 8-K | Current report | Nov 17, 2021 | Nov 17, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 16, 2021 | Nov 15, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 15, 2021 | Oct 13, 2021 |
| 8-K |
Current report
Material agreement
|
Apr 6, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Officer or director change
|
Feb 25, 2021 | Feb 19, 2021 |
| 8-K |
Current report
Officer or director change
|
Jan 25, 2021 | Jan 19, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 19, 2021 | Jan 19, 2021 |
| 8-K/A |
Amended current report
Officer or director change
|
Dec 31, 2020 | Dec 1, 2020 |
| 8-K |
Current report
Officer or director change
|
Dec 15, 2020 | Dec 11, 2020 |
| 8-K |
Current report
Acquisition or sale of assets
|
Dec 10, 2020 | Dec 7, 2020 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Other events
|
Dec 2, 2020 | Dec 1, 2020 |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTPI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1815903
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.